Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 8/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941913 | 0.86 | F10 (0.50) | F10CNR1USP2KLK1ALDH1A1 | |
| SCHEMBL4936118 | 0.85 | F10 (0.49) | F10CNR1USP2KLK1ALDH1A1 | |
| SCHEMBL4935898 | 0.85 | AKR1B1 (0.47) | F10CNR1AKR1B1USP2KLK1 | |
| SCHEMBL5334159 | 0.82 | F10 (0.47) | F10CNR1USP2KLK1ALDH1A1 | |
| SCHEMBL4938175 | 0.82 | USP2 (0.49) | F10CNR1USP2KLK1ALDH1A1 | |
| SCHEMBL4881800 | 0.76 | SMO (0.49) | SMOF10CNR1ALDH1A1NPSR1 | |
| SCHEMBL4900354 | 0.76 | F10 (0.65) | F10AKR1B1KLK1 | |
| SCHEMBL4938904 | 0.74 | F10 (0.55) | F10KLK1ALDH1A1KMT2A | |
| SCHEMBL4939620 | 0.74 | HRH3 (0.40) | F10USP2KLK1HTTSMN1; SMN2 | |
| SCHEMBL4942713 | 0.73 | NPSR1 (0.47) | F10CNR1USP2KLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | SMO 1477/4885F10 1/4885CNR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.